Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.

• 資料種別: 博士論文
• タイトル: Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
• 著者・編者: Aihara, Yosuke; Yoshiji, Hitoshi; Noguchi, Ryuichi; Kaji, Kosuke; Namisaki, Tadashi; Shirai, Yusaku; Douhara, Akitoshi; Moriya, Kei; Kawaratani, Hideto; Fukui, Hiroshi
• 著者標目: Aihara, Yosuke; Yoshiji, Hitoshi; Noguchi, Ryuichi; Kaji, Kosuke; Namisaki, Tadashi; Shirai, Yusaku; Douhara, Akitoshi; Moriya, Kei; Kawaratani, Hideto; Fukui, Hiroshi
• 出版事項: Wiley / The Japan Society of Hepatology
• 出版年月日等: 2013-11
• 出版年（W3CDTF）: 2013-11
• 並列タイトル等: 直接的レニン阻害薬であるアリスキレンはラットモデルにおいて非アルコール性脂肪肝炎の進行を抑制する
• タイトル（掲載誌）: Hepatology research
• 巻号年月日等（掲載誌）: 43 11
• 掲載巻: 43
• 掲載号: 11
• 掲載ページ: 1241-1250
• ISSN（掲載誌）: ISSN : 1386-6346
• 授与機関名: 奈良県立医科大学
• 授与年月日: 2014-03-17
• 報告番号: 甲第612号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: angiotensin-II; hepatocarcinogenesis; liver fibrosis; non-alcoholic; steatohepatitis; renin
• 対象利用者: 一般
• 一般注記: type:Thesis; AIM: Renin is a rate-limiting enzyme of the renin-angiotensin system (RAS), and several reports have shown that renin plays an important role in several pathological processes. Although RAS is known to play a pivotal role in the progression of non-alcoholic steatohepatitis (NASH), the role of renin is still obscure. The aim of the current study was to examine the effect of the clinically used direct renin inhibitor (DRI), aliskiren, on the progression of NASH in a rat model. METHODS: The effects of DRI on the choline-deficient L-amino acid-defined (CDAA) diet-induced rat NASH model was examined in conjunction with the activated hepatic stellate cells (Ac-HSC) and neovascularization, both of which are known to play important roles in liver fibrosis development and hepatocarcinogenesis, respectively. RESULTS: DRI exerted a marked inhibitory effect against liver fibrosis development and glutathione-S-transferase placental form (GST-P) positive preneoplastic lesions along with suppression of the Ac-HSC and neovascularization in a dose-dependent manner. DRI also inhibited the hepatic expressions of transforming growth factor-beta 1 (TGF-beta 1), angiotensin-II (AT-II) and vascular endothelial growth factor (VEGF). These results indicated that renin played a pivotal role in the liver fibrosis development and hepatocarcinogenesis of NASH. CONCLUSION: Because DRI is already widely used in the clinical practice with safety, this drug may represent a potential new strategy against the progression of NASH in the future.; 博士（医学）・甲612号・平成26年3月17日; identifier:Hepatology research Vol.43 No.11 p.1241-1250; identifier:13866346; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/2697; identifier:Hepatology research, 43(11): 1241-1250
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.1111/hepr.12081
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

目次

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/2697/1/01%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/2697/2/02%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/2697/6/03%e6%9c%ac%e6%96%87.pdf fulltext